PRNewswire

First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study SAN DIEGO, Dec. 8, 2024 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced data

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: